Novo Nordisk claims first GLP-1 approval in MASH скачать в хорошем качестве

Novo Nordisk claims first GLP-1 approval in MASH

In today’s headlines - 18 August 2025: Pfizer's $5.4 billion takeover of Global Blood Therapeutics three years ago is starting to look like a poor deal. Under pressure from rivals in the GLP-1 space, Novo Nordisk has been given a leg-up with a first-in-class approval for Wegovy in liver disease MASH. Tonix is preparing to launch a new therapy for fibromyalgia that analysts predict could make hundreds of millions of dollars in annual sales. A leaked version of the Make America Healthy Again programme for the Trump administration has plenty for the pharma industry to stew over. Merck KGaA has become the latest drugmaker to partner with Skyhawk Therapeutics on its RNA splicing drug discovery engine. #news #pharma #pharmanews #pharmainnovation #pharmaindustry #lifesciences #biotechnews #biopharma #drugdevelopment #drugdiscovery #merck #skyhawk #skyhawktherapeutics #rnasplicing #rna #fibromyalgia #fibromyalgiatreatment #tonixpharmaceuticals #tonix #glp1medications #glp1 #novonordisk #mash #wegovy #liverdisease #trumpadministration #ushealthcare